The Green lab's focus is on the translation of research discovery into clinical therapeutics for patients with multiple myeloma and (MM) and lymphoma. Over the past decade Dr. Green has designed and performed therapy studies in multiple myeloma models demonstrating striking efficacy, effectively eliminating >90% of MM tumors by targeting the CD38 antigen. His research has demonstrated that alpha emitting radionuclides can eliminate minimal residual disease (MRD) in preclinical models. Dr. Green has also recently demonstrated the efficacy of bispecific antibodies to treat both multiple myeloma and lymphoma. Further he is working actively on the development of chimeric antigen receptor (CAR)-T cell therapy to target myeloma.
A major focus of Dr. Green's work has been to improve the efficacy and diminish the toxicity of radioimmunotherapy. One successful method has been through our development of derivatized tumor-reactive antibodies in a non-radioactive form to facilitate localization and accumulation at tumor sites without subjecting the rest of the body to nonspecific irradiation. Through this tumor pretargeting approach we have demonstrated striking therapeutic efficacy in preclinical models.
Another focus has been to attempt to exploit the high energy, short path-length characteristics of the α-emitting radionuclide 211At. Harnessing advances in radiochemistry pioneered by collaborators the University of Washington, the team has used a closo-decaborate(2-) [B10] radiolabeling platform to demonstrate selective targeting of tumor cells in minimal residual disease settings.
Dr. Green has maintained an ongoing interest in the development of novel approaches designed to improve the efficacy of autologous stem cell transplant (ASCT) in patients with MM. Dr. Green was the prinicipal investigator of a clinical trial in which we demonstrated that bendamustine could be safely and effectively used to mobilize stem cells for ASCT in MM patients. He has also contributed to studies to evaluate more intensive induction regimens for MM patients and to evaluate the safety of increasing the dose of melphalan in a transplant conditioning regimen.
Dr. Green evaluated a novel approach (extracorporeal adsorption therapy) to optimizing the selective delivery of radiolabeled antibodies to target cells and have contributed to research exploring various monoclonal antibodies and radionuclides to improve the efficacy of RIT.